Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients

INTRODUCTION: Dalcinonacog alfa (DalcA), a novel subcutaneously administered recombinant human factor IX (FIX) variant is being developed for adult and paediatric patients with hemophilia B (HB). DalcA has been shown to raise FIX to clinically meaningful levels in adults with HB. This work aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Faraj, Alan, Le Moan, Natacha, Gorina, Eduard, Blouse, Grant E., Knudsen, Tom, Simonsson, Ulrika S. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427527/
https://www.ncbi.nlm.nih.gov/pubmed/37341915
http://dx.doi.org/10.1007/s12325-023-02570-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427527/
https://www.ncbi.nlm.nih.gov/pubmed/37341915
http://dx.doi.org/10.1007/s12325-023-02570-6

Ejemplares similares